Key points are not available for this paper at this time.
Aims: Comprehensively analyze data integrity challenges in the pharmaceutical industry, analyze regulatory observations, and propose mitigation strategies for ensuring compliance with current good manufacturing practices (cGMP), particularly for electronic data and computerized systems. Study Design: Analysis of regulatory documents, industry-standard guides, and case studies. Methodology: The study involved a comprehensive review of FDA guidance documents, warning letters, and Form 483 observations related to data integrity. Case studies of non-compliance were analyzed to identify common issues and consequences. Technical, organizational, and behavioral factors contributing to data integrity problems were examined. Mitigation strategies and best practices were compiled based on industry guidelines and expert recommendations. Results: Data integrity violations often involve data falsification, poor retention, and electronic record manipulation. Non-compliant firms have faced severe penalties for non-compliance. Challenges include legacy systems, complex data management, inadequate training, and global supply chains. Mitigation strategies involve data governance, risk-based validation, access controls, comprehensive training, and advanced technologies like blockchain. Conclusion: Data integrity remains a critical challenge in the pharmaceutical industry, requiring a holistic approach that combines technological solutions with organizational and cultural best practices. Implementing robust data governance systems, fostering a quality culture, and leveraging advanced technologies can significantly improve compliance and reduce risks associated with data integrity issues.
Pravin Ullagaddi (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: